E & P Valuation $24.40
We have increased our probability of success for NNZ-2591 in Phelan-McDermid syndrome and other indications in the pipeline (Pitt Hopkins, Angelman, Prader-Willi). The probability of success in Phase 2 for PMS has been increased to 100%, while for the other indications this probability has been increased by 5pp.
Neuren Media and Analyst Coverage, page-579
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.65 |
Change
-0.080(0.39%) |
Mkt cap ! $2.636B | |||
| Open | High | Low | Value | Volume |
| $20.90 | $21.30 | $20.49 | $4.058M | 195.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 51 | $20.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.66 | 49 | 4 |
View Market Depth
| Last trade - 15.46pm 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$20.72 |
Change
-0.080 ( 0.20 %) |
||||
| Open | High | Low | Volume | ||
| $20.93 | $21.30 | $20.50 | 83102 | ||
| Last updated 15.59pm 22/05/2024 ? | |||||
| NEU (ASX) Chart |